| ORIC Stock | | | USD 11.14 0.01 0.09% |
A thorough review of Oric Pharmaceuticals's financial statements uncovers patterns in revenue and profitability. Core fundamentals used to assess intrinsic value are listed below: Oric Pharmaceuticals's financial disclosures allow investors to separate accounting earnings from economic reality. Key fundamentals are provided below:
Market Capitalization | Earnings Share -1.47 |
Across one hundred twenty fundamental ratios, Oric Pharmaceuticals offers a broad dataset for trend analysis and peer comparison. It may be useful to review Oric Pharmaceuticals' up-to-date fundamental drivers against all of the trends between
2010 and 2026.
Recent disclosures position Total Revenue within a consolidating cycle. The prior-year reading for Total Revenue was 0.00. As of yesterday,
Gross Profit is anticipated to decline to approximately -1.3
M.
Oric Pharmaceuticals Correlation positions Oric Pharmaceuticals relative to competitors. This adds peer-relative context for the stock.
Exploring Oric Stock for the first time? Start with our
How to Buy Oric Stock step-by-step guide. It provides a clear overview of how to add Oric Pharmaceuticals to your portfolio. It is a useful companion to the data and analysis available on this page for Oric Stock.
Reference data derived from Oric Pharmaceuticals' reporting presents period-over-period observations that support fundamental screening workflows. Oric Pharmaceuticals has a market cap of 1.25 B, ROE of -41.27%.
Inputs for Oric Pharmaceuticals come from periodic company reporting and market reference feeds and are mapped into a consistent reporting framework. Some fields can appear with publication lag. This section presents reference data and historical patterns only and does not constitute an investment recommendation or advice.
This content is curated and reviewed by:
Michael Smolkin - Member of Macroaxis Board of Directors
Last reviewed on March 18th, 2026